24 results about "Virology" patented technology

The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor.

The invention relates to the technical field of virus detection, and particularly discloses a novel coronavirus 2019-nCoV double-target antibody detection microsphere complex combination, a preparation method, a kit and a using method of the kit. A microsphere complex combination coupled with an antigen is used; the coupling antigen comprises an S protein of the novel coronavirus 2019-nCoV and anN protein of the novel coronavirus 2019-nCoV, the amino acid sequence of the S protein is as shown in SEQ NO: 1, and the amino acid sequence of the N protein is as shown in SEQ NO: 2. The prepared microsphere complex combination can perform double-target detection on an S antibody and an N antibody, and fully reflects the effect that two main antigens of the novel coronavirus (2019-nCoV) stimulatean organism to generate a specific antibody.

The invention discloses one group of nucleic acid aptamers capable of specifically bonding with tuberculosis mycobacterium Beijing genotype strain surface lipolysaccharide namely mannose modified mannosylated lipoarabinomannan (ManLAM) and application of the nucleic acid aptamers. The aptamers are specific to small-molecular single-chain DNA (ssDNA) of the ManLAM, and have a nucleotide sequence as shown in the SEQ ID No.1-5. The ssDNA has functions similar to those of a monoclonal antibody, and can be directly and specifically bonded with ManLAM. By adopting an enzyme-linked oligonucleotide assay (ELONA) method, the ManLAM antigen in serum of patients with pulmonary tuberculosis, extrapulmanory tuberculosis and the like can be quickly effectively detected in 2 hours, the ManLAM antigen in sputum of an active pulmonary tuberculosis patient can be directly identified, and the detection sensitivity on the Man LAM antigen can be 0.035mu g/mL. The aptamers are simple to prepare and low in cost, and can be used as an effective novel reagent for diagnosing the mycobacterium tuberculosis antigen of early and latent tuberculosis.

The invention relates to the technical field of genetic engineering of recombinant viruses, in particular to an application and preparation method of a candidate strain of a human type-3 adenovirus expressed human type-14 adenovirus neutralization epitope vaccine. Two human type-14 adenovirus neutralization epitopes are respectively embedded to hexons of human type-3 adenoviruses to be displayed on the surfaces of the hexons. The candidate strain of the vaccine is capable of inducing strong anti-HAdv14 and anti-HAdv3 infection immunoreactions and can be used for preparation of bivalent vaccines for prevention of HAdv14 and HAdv3 infection.

The invention relates to a recombinant chimeric antigen of treponema pallidum. The recombinant chimeric antigen is formed by connecting an amino acid sequence as shown in SEQ ID NO.12, a first flexible linker, an amino acid sequence as shown in SEQ ID NO.9, a second flexible linker and an amino acid sequence as shown in SEQ ID NO.13 in series. The recombinant chimeric antigen can be used for serological detection of treponema pallidum antibody, and has improved dissolving expression capability, activity and thermal stability. The invention also relates to a method for preparing the recombinantchimeric antigen.

The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.

A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-thymine nucleotide, or a phosphate prodrug thereof, optionally in combination therapy with other drugs for the treatment of HBV.

The invention belongs to the field of medical detection instruments and particularly relates to a mycoplasma culture plate automatic interpreter. The mycoplasma culture plate automatic interpreter comprises a culture assembly, an analysis assembly, a moving assembly, a main controller, a display screen, a printer and a shell carrying the above assemblies. For the mycoplasma culture plate automaticinterpreter provided by the invention, by arranging the culture assembly, the analysis assembly, the moving component, the main controller, the display screen and the printer, operation of artificialculture and manual interpretation in traditional operation is replaced, the working efficiency is greatly improved, and automatic operation of mycoplasma identification and drug sensitivity analysisis achieved.

The invention belongs to the technical field of nucleic acid detection, and discloses a primer combination and a kit for identifying an African swine fever virus gene deletion strain and an African swine fever epidemic strain by using a centrifugal microfluidic chip. The kit comprises a microfluidic chip, an isothermal amplification premixed solution, an isothermal amplification enzyme solution and a positive standard. The invention further relates to a detection method adopting the kit. The detection method comprises the steps of coating of a primer composition, extraction of a nucleic acid sample to be detected, LAMP reaction and result interpretation. The detection system can rapidly, conveniently, efficiently, specifically and sensitively identify and diagnose African swine fever gene deletion strain and African swine fever wild strain under isothermal conditions, does not need expensive and complex instruments, provides a novel portable detection platform for epidemiological detection and prevention and control of African swine fever, greatly reduces detection cost, is easy to popularize in a large range, and has broad market prospects.

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

The invention provides a phagemid vector construction method for constructing a phage antibody library and an antibody screening method. Phagemids are filamentous phagemids containing restriction enzyme cutting sites of bovine thrombin between coat protein PIII coding genes and target gene insertion sites. The restriction enzyme cutting sites of bovine thrombin are introduced into the phagemids, and hydrolytic cleavage of protein is carried out, so that the background in which the phagemids are non-specifically eluted is reduced. By using the phagemids of the present invention, the antibody screening efficiency is higher, and the problem of low screening efficiency in a phage display technology in the prior art is solved.

The invention relates to a hybridoma cell strain secreting an anti-maize chlorotic dwarf virus (MCDV) monoclonal antibody. The hybridoma cell strain is collected in China Center for Type Culture Collection with the collection name of hybridoma cell MCDV and the collection number of CCTCC NO: C201486. The hybridoma cell strain provided by the invention has the beneficial effects that, 1) the provided hybridoma cell strain secretes the anti-maize chlorotic dwarf virus specific monoclonal antibody, TAS (three antibodies sandwich)-ELISA (enzyme linked immunosorbent assay) and dot-ELISA and other immunological methods established by taking the monoclonal antibody as the core and kits established by using the methods can detect maize chlorotic dwarf virus with high specificity, accuracy and sensitivity; 2) by using the monoclonal antibody prepared according to the invention to detect the maize chlorotic dwarf virus, expensive instruments and reagents are not required; and 3) the monoclonal antibody prepared according to the invention can be effectively used for detecting the maize chlorotic dwarf virus in imported corn and other maize chlorotic dwarf virus hosts.

An aqueous extract of Lawsonia inermis comprising forming an extraction from 1% to 20% of dried Lawsonia inermis leaves with water. The antibiotics polymyxin B, clindamycin, and gentamycin are each added to the water before or after extraction in the amount of 0.001% to 0.003%. After forming the aqueous extract of Lawsonia inermis, it has no antibiotic activity and the antibiotics are not detectable by chemical analysis. The aqueous extract of Lawsonia inermis is stable for at least 28 days for the topical treatment of wounds and has been stable up to two years in clinical testing. The aqueous extract of Lawsonia inermis extract is applied with a spray to the surface of the wound, followed by the application of an extract-soaked gauze dressing to the surface of the wound. The extract is effective on various types of wounds and also in healing wounds in patients who are not healing with traditional therapies.

Vaccine compositions and methods are described for providing immunity to porcine circovirus type two (PCV2) genotypes including by administration of a recombinant PCV2 capsid polypeptide which comprises antigenic epitopes from the capsids of multiple PCV2 genotypes. In other embodiments a recombinant chimeric porcine circovirus is provides for use as a vaccine that combines the nonpathogenic backbone of porcine circovirus type 1 (PCV1) with the sequences encoding a PCV2 capsid polypeptide comprises antigenic epitopes from the capsids of multiple PCV2 genotypes.

The invention provides an IsdB antigen epitope peptide for diagnosing or preventing staphylococcus aureus infection. The IsdB antigen epitope peptide comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO: 8. The invention also provides an application of the antigen epitope peptide in preparation of drugs for diagnosing, preventing or treating staphylococcus aureus infection. According to the present invention, an antibody dominant epitope peptide of iron-regulated surface determinant B of staphylococcus aureus is determined through screening and has strong immunogenicity. The dominant epitope peptide has amino acid sequences that are conservative in a variety of S. aureus strains, so that the dominant epitope peptide can be used in preparation of diagnostic reagents against staphylococcus aureus infection. The IsdB antigen epitope peptide can also be used for preventing or treating other S. aureus infections.